Effect of a κ-opioid agonist, i.v. JNJ-38488502, on sensation of colonic distensions in healthy male volunteers

Neurogastroenterology and Motility

Volumn 21, Issue 3, 2009, Pages 281-290

  Floyd, B N ^b   Camilleri, M ^a,b   Busciglio, I ^b   Sweetser, S ^b   Burton, D ^b   Wong, G Y ^c   Kell, S ^c   Khanna, S ^c   Hwang, S ^c   Zinsmeister, A R ^a  

^a MAYO CLINIC   (United States)

^b Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^c ALZA CORPORATION   (United States)

Author keywords

opioid; Functional gastrointestinal disorders; Visceral pain

Indexed keywords

JNJ 38488502; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; PLACEBO; PROLACTIN; UNCLASSIFIED DRUG;

ADULT; AGITATION; ANXIETY; ARTICLE; CLINICAL TRIAL; COLON DILATATION; COMPLIANCE (PHYSICAL); CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; INTESTINE PRESSURE; MALE; MYALGIA; NORMAL HUMAN; PAIN; PARESTHESIA; PERCEPTIVE THRESHOLD; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SENSATION; SIDE EFFECT; SINGLE DRUG DOSE; THINKING; URINE VOLUME;

ACETAMIDES; ADOLESCENT; ADULT; ANALGESICS, OPIOID; COLON; CROSS-OVER STUDIES; DILATATION, PATHOLOGIC; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PAIN THRESHOLD; PLACEBOS; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; SENSATION; YOUNG ADULT;

EID: 60649088515     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01202.x     Document Type: Article

References (36)

1. Andresen V, Camilleri M. Challenges in drug development for functional gastrointestinal disorders. Part II: visceral pain. Neurogastroenterol Motil 2006 18 : 354 60.
2. Holtmann G, Goebell H, Talley NJ. Functional dyspepsia and irritable bowel syndrome - is there a common pathophysiologic basis? Am J Gastroenterol 1997 92 : 954 9.
3. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site specific evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995 40 : 1607 13.
4. Satoh M, Minami M. Molecular pharmacology of the opioid receptors. Pharmacol Ther 1995 68 : 343 64.
5. Butelman ER, Ball JW, Kreek MJ. Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonists in rhesus monkeys. Psychopharmacology (Berl) 2002 164 : 115 20.
6. Eisenach JC, Carpenter R, Curry R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain 2003 101 : 89 95.
7. Gottlieb HB, Kapusta DR. Endogenous central kappa-opioid systems augment renal sympathetic nerve activity to maximally retain urinary sodium during hypotonic saline volume expansion. Am J Physiol 2005 289 : R1289 96.
8. Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995 40 : 2244 9.
9. Delgado-Aros S, Chial HJ, Camilleri M et al. Effects of a κ-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol 2003 284 : G558 66.
10. Delgado-Aros S, Chial HJ, Cremonini F et al. Effects of asimadoline, a κ-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003 18 : 507 14.
11. Delvaux M, Beck A, Jacob J, Bouzamondo H, Weber FT, Frexinos J. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004 20 : 237 46.
12. Talley NJ, Choung RS, Camilleri M, Dierkhising RA, Zinsmeister AR. Asimadoline, a kappa opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008 27 : 1122 31.
13. Szarka LA, Camilleri M, Burton D et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007 5 : 1268 75.
14. Joshi SK, Lamb K, Bielefeldt K, Gebhart GF. Arylacetamide kappa-opioid receptor agonists produce a tonic- and use-dependent block of tetrodotoxin-sensitive and -resistant sodium currents in colon sensory neurons. J Pharmacol Exp Ther 2003 307 : 367 72.
15. Machelska H, Pflüger M, Weber W et al. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther 1999 290 : 354 61.
16. Coruzzi G, Morini G, Coppelli G, Bertaccini G. The contractile effect of fedotozine on guinea pig isolated intestinal cells is not mediated by kappa opioid receptors. Pharmacology 1998 56 : 281 4.
17. Rivière PJ. Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol 2004 141 : 1331 4.
18. Vanderah TW, Largent-Milnes T, Lai J et al. Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors. Eur J Pharmacol 2008 583 : 62 72.
19. Kramer HJ, Uhl W, Ladstetter B, Backer A. Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. Br J Clin Pharmacol 2000 50 : 227 35.
20. Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 2005 30 : 2254 62.
21. Goletiani NV, Mendelson JH, Sholar MB, Siegel AJ, Skupny A, Mello NK. Effects of nalbuphine on anterior pituitary and adrenal hormones and subjective responses in male cocaine abusers. Pharmacol Biochem Behav 2007 86 : 667 77.
22. Chesterfield M, Janik J, Murphree E, Lynn C, Schmidt E, Callahan P. Orphanin FQ/nociceptin is a physiological regulator of prolactin secretion in female rats. Endocrinology 2006 147 : 5087 93.
23. Talley NJ, Phillips SF, Wiltgen CM, Zinsmeister AR, Melton LJ III. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990 65 : 1456 79.
24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983 67 : 361 70.
25. Hammer HF, Phillips SF, Camilleri M, Hanson RB. Rectal tone, distensibility, and perception: reproducibility and response to different distensions. Am J Physiol 1998 274 : G584 90.
26. Cremonini F, Houghton LA, Camilleri M et al. Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. Neurogastroenterol Motil 2005 17 : 810 20.
27. Floyd BNI, Camilleri M, Andresen V, Esfandyari T, Busciglio I, Zinsmeister AR. Comparison of mathematical methods for calculating colonic compliance in humans: power exponential, computer-based, and manual linear interpolation models. Neurogastroenterol Motil 2008 20 : 330 5.
28. Bart G, Borg L, Schluger JH, Green M, Ho A, Kreek MJ. Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther 2003 306 : 581 7.
29. Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R, Rajagopalan R. Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol 1994 34 : 1126 32.
30. Kest B, Sarton E, Dahan A. Gender differences in opioid-mediated analgesia: animal and human studies. Anesthesiology 2000 93 : 539 47.
31. Wise EA, Price DD, Myers CD et al. Gender role expectations of pain: relationship to experimental pain perception. Pain 2002 96 : 335 42.
32. Chang L, Mayer EA, Labus JS et al. Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol 2006 291 : R277 84.
33. Berman SM, Naliboff BD, Suyenobu B et al. Sex differences in regional brain response to aversive pelvic visceral stimuli. Am J Physiol 2006 291 : R268 76.
34. Labus JS, Naliboff BN, Fallon J et al. Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis. Neuroimage 2008 41 : 1032 43.
35. Mangel AW, Bornstein JD, Hamm LR et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008 28 : 239 49.
36. Puehler W, Rittner HL, Mousa SA et al. Interleukin-1 beta contributes to the upregulation of kappa opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation. Neuroscience 2006 141 : 989 98.